Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Italy
33 of 42 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Bologna, Castelfranco Veneto, Florence, Meldola, Milan, Monza, Naples, Novara, Orbassano, Padova, Palermo, Rome, Turin, Udine, Verona
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 1Not yet taking people in ItalyStudy of INCA036978 in Participants With Myeloproliferative Neoplasms
- Where
- Bologna, Milan, Roma, Udine
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00 - Phase 3Not yet taking people in ItalyA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Bari, Bergamo, Bologna, Catania, Florence, Genova, Meldola, Milan, Novara, Pavia, Rome, Torino, Udine, Verona
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 1Taking peopleA Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 256 worldwide
- Run by
- Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
See details and how to joinNCT06343805 · EU 2025-522033-64-00 - Phase 3Taking peopleA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- Where
- Alexandria, Bologna, Florence, Varese
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06351631 · EU 2023-506996-89-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Genoa, Meldola, Milan, Pisa, Rome, Turin
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Not yet taking people in ItalyA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Ancona, Bologna, Catania, Ferrara, Florence, Meldola, Milan, Rome, Turin, Udine
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 1Taking peopleA Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00 - Phase 2Active, not recruitingStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- Where
- Bologna, Catania, Florence, Meldola, Milan, Rome
- Age
- 18 years and over
- People
- 68 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06517875 · EU 2024-518225-15-00 - Phase 3Taking peopleINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
- Where
- Alexandria, Ancona, Bergamo, Bologna, Cesena, Florence, Forli', Genoa, Meldola, Milan, Monza, Naples, Novara, Pavia, Pesaro, Rome, Turin, Udine, Verona, Vicenza
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00 - Phase 1Taking peopleA Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- Where
- Florence, Ravenna, Rome
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Prelude Therapeutics Incorporated
See details and how to joinNCT07469891 · EU 2026-525484-40-00 - Phase 1/2Taking peopleA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Alexandria, Aviano, Bologna, Brescia, Catania, Meldola, Milan, Monza, Novara, Turin, Varese
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - Phase 2Active, not recruitingA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Bologna, Genoa, Meldola, Milan, Novara, Pavia, Rome, Turin
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 - Phase 2Not yet taking people in ItalyRVU120 Rollover Study
- Where
- Bari
- Age
- 18 years and over
- People
- 14 worldwide
- Run by
- Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00 - Phase 2Terminated(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Bologna, Florence, Salerno, Verona
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 3Taking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Alexandria, Ancona, Bologna, Brescia, Catania, Florence, Meldola, Milan, Novara, Orbassano, Palermo, Pavia, Pesaro, Ravenna, Reggio Emilia, Rome, Turin, Varese
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - Phase 1/2Taking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Bologna, Meldola, Milan
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - Phase 1/2Taking peopleA Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)
- Where
- Bologna, Florence, Meldola, Naples, Reggio Calabria, Rome, Turin, Udine
- Age
- 18 years and over
- People
- 27 worldwide
- Run by
- iOnctura SA
See details and how to join2024-515252-20-00 - Phase 1Not yet taking people in ItalyA Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Where
- Bergamo, Florence, Milan, Verona
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07008118 - Phase 3Taking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Allessandria, Bologna, Brindisi, Cagliari, Ferrara, Florence, Genoa, Lecce, Milan, Modena, Naples, Orbassano, Pavia, Reggio Calabria, Roma, Rozzano, Varese, Verona
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 1/2Taking peopleA Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
- Where
- Bologna, Florence, Meldola, Rozzano, Udine
- Age
- 18 years and over
- People
- 26 worldwide
- Run by
- iOnctura
See details and how to joinNCT06887803 - No phaseNot yet taking people in ItalyENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
- Where
- Torino
- Age
- 18 years and over
- People
- 25
- Run by
- Carmen Fava
See details and how to joinNCT07518940 - Phase 3Active, not recruitingStudy on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- Where
- Ancona, Bari, Bergamo, Bologna, Catania, Cuneo, Florence, Meldola, Milan, Novara, Palermo, Reggio Calabria, Reggio Emilia, Rome, Turin, Udine
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00 - No phaseTaking peopleFeasibility of a Multi-omics Platform for Hematological Malignancies
- Where
- Parma
- Age
- 2 years and over
- People
- 1,040
- Run by
- Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07445438 - No phaseTaking peopleChemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
- Where
- Parma
- Age
- 1 year and over
- People
- 250
- Run by
- Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07445984